Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 8 pages · English
Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to present its activities report for the quarter ended 31 December 2025 (Q2 FY2026), together with its Appendix 4C Quarterly Cash Flow Report. HIGHLIGHTS • US Food and Drug Administration (FDA) grants Rare Pediatric Disease D
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Binding Commitments Received for a $4 Million Placement
- Trading Halt
- Neurotech receives $4.73m R&D Tax Incentive Refund
- US FDA Rare Pediatric Disease Designation in Rett syndrome
- Appendix 4E & Annual Report to shareholders
Later from Neurotech International
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Positive 90-day GLP toxicology study results in non-rodents
- Appendix 4D & Half Year Report
- NTI initiates First Clinical Site for Phase 3 ASD Trial
- NTI secures Notices of Allowance for US patent applications
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International